Tempus AI

Tempus AI Short-term Debt

The Short-Term Debt of Tempus AI (TEM) as of Nov 20, 2026 is 13.36 M USD. In the previous year, Short-Term Debt was 6.46 M USD — a change of 106.77% (higher).

Short-term Debt

13.36 MUSD

YoY

106.77%

Last updated:

Short-Term Debt of Tempus AI is 2025 13.36 M USD. Short-Term Debt of Tempus AI was 2024 6.46 M USD. It decreases by 106.77% higher compared to the previous year.

The Tempus AI Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2019
1.15 M USD
Jan 1, 2020
723,000.00 USD
Jan 1, 2021
419,000.00 USD
Jan 1, 2022
6.36 M USD
Jan 1, 2023
6.44 M USD
Jan 1, 2024
6.46 M USD
Jan 1, 2025
13.36 M USD
The Tempus AI Short-term Debt history
YEARShort-term DebtYoY
13.36 MUSD+106.77%
6.46 MUSD+0.34%
6.44 MUSD+1.24%
6.36 MUSD+1,417.42%
419,000.00USD-42.05%
723,000.00USD-37.19%
1.15 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Short-Term Debt of Tempus AI is 13.36 M USD in 2025.

Short-Term Debt of Tempus AI changed from 6.46 M USD to 13.36 M USD, representing a 106.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Tempus AI since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Tempus AI historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Tempus AI

All Key Metrics — Tempus AI